サンプル依頼リスト カート
  • English
  • Korean
表紙：アレルギー性鼻結膜炎の世界市場：2023年～2030年
市場調査レポート
商品コード
1382519

アレルギー性鼻結膜炎の世界市場：2023年～2030年

Global Allergic Rhino-Conjunctivitis Market - 2023-2030

出版日
ページ情報
英文 187 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
アレルギー性鼻結膜炎の世界市場：2023年～2030年
出版日: 2023年11月17日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

アレルギー性鼻結膜炎は、特に先進国で小児によくみられる慢性疾患です。鼻づまりやくしゃみなどの鼻症状だけでなく、倦怠感や咳などの全身症状を引き起こすこともあります。古典的な「花粉症」は、花粉の季節に鼻水、くしゃみ、目のかゆみがある子供ではすぐにわかるが、通年鼻づまりの子供ではアレルギー性鼻結膜炎の診断が見逃されがちです。

医師の診察、処方、治療などヘルスケアにかかる費用は高額であるため、アレルギー性鼻結膜炎は経済的に大きな影響を与える可能性があります。また、労働効率の低下や欠勤の増加にもつながり、労働者にとっても雇用主にとっても有害です。アレルギー性鼻結膜炎が効果的に治療されない場合、副鼻腔炎、耳の感染症、耳の感染症などの結果に進展する可能性があります。これらの問題はさらなる不快感につながり、より多くの医療措置が必要となる可能性があります。

市場力学：促進要因と阻害要因

汚染レベルの上昇

アレルギーの有病率の増加、汚染レベルの上昇、利用可能な治療オプションに関する意識の高まりは、市場成長を促進する主な要因です。例えば、WHO 2022によると、環境大気汚染と家庭大気汚染の複合的な影響は、年間670万人の早死と関連しており、環境（屋外）大気汚染は、2019年に世界で420万人の早死を引き起こしたと推定されています。

さらにEPAによると、2022年には米国で約6,500万トンの汚染が大気中に排出されました。これらの排出物は主に、オゾンや微粒子の形成、酸の沈着、視界障害に寄与しています。そのため、汚染レベルの上昇が市場の成長を加速させています。

アレルギーと免疫学の分野では、常に新しい治療法、薬剤、治療法が開発されています。医学の進歩の結果、アレルギー性鼻結膜炎を治療するための効率的な製品が多種多様に生産されています。アレルギーの有病率の増加は、汚染の増加や気候パターンの変化などの環境変化の結果です。

市場力学：抑制要因

アレルギー性鼻結膜炎市場は成長を続けているが、その進行を妨げるいくつかの抑制要因があります。例えば、アレルギー性鼻結膜炎の症状を治療する薬はいくつかあるが、すべての人がその恩恵を受けられるわけではないです。一時的な緩和や不快な副作用しか得られない人もいます。

さらに、抗ヒスタミン薬の中には、特に以前の世代のものは、眠気などの副作用があり、使用者のQOLを低下させる可能性があります。新薬に関連する副作用は少なくなってきていますが、安全性の懸念は、特に特定の患者集団にとっては、依然として障壁となりえます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 汚染レベルの増加
      • アレルギーの増加
  • 抑制要因
      • 現在の治療法の有効性の限界
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • パイプライン分析
  • アンメットニーズ
  • DMI意見

第6章 COVID-19分析

第7章 薬剤タイプ別

  • コルチコステロイド（鼻用および局所用）
  • うっ血除去薬
  • 抗ヒスタミン薬
  • 肥満細胞安定剤
  • その他

第8章 投与経路別

  • 経口
  • 経鼻
  • 局所
  • その他

第9章 年齢層別

  • 小児
  • 成人

第10章 流通チャネル別

  • 病院薬局
  • オンライン薬局
  • 小売薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Sun Pharmaceutical Industries
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Merck & Co., Inc
  • Novartis AG
  • Haleon Group
  • Lofarma S.p.A
  • ALK-Abello A/S
  • Stallergenes Greer
  • HAL Allergy B.V.
  • Hikma Pharmaceuticals PLC
  • Bausch & Lomb

第14章 付録

目次
Product Code: PH7433

Overview

Allergic rhino conjunctivitis is a common chronic disorder in children, especially in developed countries. It does not cause nasal symptoms only (such as congestion and sneezing) but may also cause general complaints such as fatigue and cough. Although classic "hay fever" is easily recognised in children who have a runny nose, sneezing, and itchy eyes during the pollen season, the diagnosis of allergic rhino conjunctivitis is often missed in children with perennial nasal congestion.

Due to the high expense of healthcare, including doctor visits, prescriptions, and treatments, allergic rhino conjunctivitis can have a substantial financial impact. It can also result in lower efficiency at work and more absenteeism, which is harmful to both workers and employers. If allergic rhino conjunctivitis is not treated effectively, it might progress to consequences including sinusitis, an infection of the ears, or ear infections. These issues could lead to further discomfort and necessitate more medical attention.

Market Dynamics: Drivers and Restraints

The increasing pollution levels

The increasing prevalence of allergies, rising pollution levels, and growing awareness about the available treatment options are major factors driving market growth. For instance, according to WHO 2022, stated that, the combined effects of ambient air pollution and household air pollution are associated with 6.7 million premature deaths annually and ambient (outdoor) air pollution is estimated to have caused 4.2 million premature deaths worldwide in 2019.

Moreover, according to EPA, in 2022, about 65 million tons of pollution were emitted into the atmosphere in the United States. These emissions mostly contribute to the formation of ozone and particles, the deposition of acids, and visibility impairment. Thus rise of pollution levels accelerates the market growth.

New therapeutic approaches, drugs, and therapies are always being developed in the fields of allergy and immunology. A greater variety of efficient products for treating allergic rhino conjunctivitis have been produced as a result of medical science advancements. A increasing prevalence of allergies is a result of environmental changes such increased pollution and shifting climatic patterns.

Market Dynamics: Restraint

While the allergic rhino conjunctivitis market continues to grow, there are several restraining factors that can impede its progress. For instance, while there are several drugs available to treat the symptoms of allergic rhino conjunctivitis, not everybody can benefit from them. Some people may only get temporary relief or unpleasant side effects, which makes them uncomfortable and less likely to follow through with prescribed therapies.

In addition, some antihistamines, especially those from earlier generations, might have adverse effects like sleepiness that lower users' quality of life. Although there are fewer adverse effects associated with newer drugs, safety concerns can still be a barrier, particularly for certain patient populations.

Segment Analysis

The global allergic rhino-conjunctivitis marketis segmented based on drug type, route of administration, age group, distribution channel and region.

The antihistamines segment from the type segment accounted for approximately 41.7% of allergic rhino-conjunctivitis share

Antihistamines allergic rhino conjunctivitis symptoms by inhibiting the action of histamine, a chemical released by the body when it feels it is under attack from an allergen. Antihistamines that target the histamine H1 receptor can help patients with allergic rhino conjunctivitis improve and maintain their quality of life. A classification based on their detailed characteristics is required for the more effective and safer second-generation drugs recommended by various guidelines. Oral antihistamines, in general, have been shown to relieve histamine-mediated symptoms associated with allergic rhino conjunctivitis effectively.

Second-generation antihistamines are useful for many patients with mild symptoms who require as-needed treatment because their onset of action is typically within 15 to 30 minutes. They are considered safe for children over the age of two. This segment is expected to dominate the market growth in the forecast period due to the increasing launches of antihistamines to treat allergic rhino conjunctivitis.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

Revenue growth in North America is attributed to the rising number of patients with rhino conjunctivitis, government initiatives to promote awareness, and the rising demand for treatment are some of the key factors responsible for the market revenue growth in this region.

For instance, according to CDC, allergic conjunctivitis is the inflammation of the lining of the eye (conjunctiva) due to exposure to allergens like those in pollen. Allergic conjunctivitis is found in up to 30% of the general population and as many as 7 out of 10 of patients with allergic rhinitis. Symptoms from allergic conjunctivitis include red, watery, or itchy eyes. Thus, rise of disease in the region accelerates the region growth.

Due to the rising prevalence of allergic disorders, the dominance of major market players, and R&D for the creation of efficient and safer allergen-specific immunotherapy procedures, the market for allergy immunotherapies is expected to grow in Europe over the forecast period.

COVID-19 Impact Analysis

COVID-19, caused by the novel coronavirus SARS-CoV-2, primarily affects the respiratory system. While the virus primarily manifests with symptoms such as fever, cough, and difficulty breathing, there have been reports of various other symptoms and complications, including effects on the eyes and exacerbation of pre-existing conditions such as allergic rhino conjunctivitis.

The pandemic's focus on COVID-19 may make it more difficult to treat allergic rhino conjunctivitis. Due to concerns about exposure to COVID-19, people may postpone seeking medical assistance for allergy symptoms, which can result in mismanaged or improperly managed allergies. Individuals with allergic rhino conjunctivitis may be harmed by wearing masks, a typical COVID-19 prevention technique.

Market Segmentation

By Drug Type

  • Corticosteroids (Nasal and Topical)
  • Decongestants
  • Antihistamines
  • Mast Cell Stabilizers
  • Others

By Route of Administration

  • Oral
  • Nasal
  • Topical
  • Others

By Age Group

  • Pediatric
  • Adult

By Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

major global players in the market include: Sun Pharmaceutical Industries, Merck & Co., Inc, Novartis AG, Haleon Group, Lofarma S.p.A, ALK-Abello A/S, Stallergenes Greer, HAL Allergy B.V., Hikma Pharmaceuticals PLC, Bausch & Lomb and among others.

Key Developments

  • In May 2023, Stallergenes Greer, a biopharmaceutical company the initiation of a Phase III clinical study (YOBI, Young patients and Birch allergy) to confirm the safety and efficacy of Staloral Birch in children and adolescents with birch pollen-induced allergic rhino-conjunctivitis with or without asthma.
  • In August 2021, Hikma Pharmaceuticals PLC (Hikma, Group), company introduced the RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) in the US. RYALTRIS is the only fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular in one easy-to-use nasal spray.

Why Purchase the Report?

  • To visualize the global allergic rhino-conjunctivitis market segmentation based on drug type, route of administration, age group, distribution channel and region as well as understandkey commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of allergic rhino-conjunctivitis market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global allergic rhino-conjunctivitis market report would provide approximately 69 tables, 58 figures and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Age Group
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Market Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing of pollution levels
      • 4.1.1.2. Increasing prevalence of allergies
  • 4.2. Restraints
      • 4.2.1.1. Limited efficacy of current treatments
    • 4.2.2. Opportunity
    • 4.2.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 7.1.2. Market Attractiveness Index, By Drug Type
  • 7.2. Corticosteroids (Nasal and Topical) *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Decongestants
  • 7.4. Antihistamines
  • 7.5. Mast Cell Stabilizers
  • 7.6. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Nasal
  • 8.4. Topical
  • 8.5. Others

9. By Age Group

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.1.2. Market Attractiveness Index, By Age Group
  • 9.2. Pediatric*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Adult

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Sun Pharmaceutical Industries *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Merck & Co., Inc
  • 13.3. Novartis AG
  • 13.4. Haleon Group
  • 13.5. Lofarma S.p.A
  • 13.6. ALK-Abello A/S
  • 13.7. Stallergenes Greer
  • 13.8. HAL Allergy B.V.
  • 13.9. Hikma Pharmaceuticals PLC
  • 13.10. Bausch & Lomb

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us